Sanara MedTech Inc.

Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanara MedTech (SMTI) reports record revenue in 2022, eyes market expansion

Sanara MedTech had a strong financial performance in 2022, despite increased expenses leading to a higher net loss. The company is strategically positioned to capitalize on opportunities in the Surgical Wound Care market and leverage partnerships for growth.

Sanara MedTech Inc. reports robust revenue growth and strategic advancements

Sanara MedTech Inc. demonstrated strong revenue growth and cost management in Q1 2023, with a focus on FDA clearances and product commercialization.
While facing supply challenges with Allocyte, the company's capital-raising efforts and strategic plans for BIASURGE offer promising opportunities for growth.
Overall, Sanara MedTech Inc. is positioned to capitalize on its product portfolio and partnerships to drive future success and market expansion.

Sanara MedTech reports robust Q2 growth amidst operational challenges

Sanara MedTech's Q2 2023 performance reflects strong revenue growth and improved financials, despite challenges like slower hiring and supply issues impacting sales.
The company's strategic strengths lie in innovation, market expansion efforts, and a proactive approach to addressing operational challenges for sustained growth.
Opportunities for Sanara MedTech include new product launches, international expansion, and strategic acquisitions to drive future revenue and market competitiveness.

Sanara MedTech (SMTI) posts record Q3 revenue, eyes growth opportunities

Sanara MedTech (SMTI) reported strong financial performance in Q3 with record revenues and improved margins, driven by strategic acquisitions and operational efficiencies.
While facing challenges like supply issues and increased expenses, the company is focused on leveraging new product launches and growth strategies for future success.
Opportunities lie in expanding market presence with innovative products, bundling strategies, and efficient operations to drive growth and enhance customer value.
Overall, Sanara MedTech's commitment to innovation, cost-effectiveness, and market expansion positions it well for long-term success and leadership in the healthcare industry.

Sanara MedTech Inc. reports record revenue, eyes growth through innovation

Sanara MedTech Inc. delivered strong revenue growth in 2023, driven by sales of soft tissue repair products.
While facing profitability challenges, the company's strategic focus on innovation and cost management bodes well for future growth.
Opportunities lie in expanding market presence, product offerings, and strategic partnerships to drive revenue and enhance competitiveness.
Efforts to improve outcomes in chronic wound care and lower costs demonstrate a commitment to long-term sustainability and market leadership.

Sanara MedTech (SMTI) reports record revenue and strategic growth initiatives

Sanara MedTech (SMTI) demonstrated strong financial performance in Q3 2024, with record revenue and positive EBITDA, driven by growth in soft tissue product sales.
Strategic investments in ChemoMouthpiece, LLC, and the upcoming launch of Tissue Health Plus (THP) position the company for future market disruption and revenue expansion.
While challenges exist in the Surgical segment's profitability, Sanara's overall performance and strategic initiatives present opportunities for sustained growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FORT WORTH, TX, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, wound and skincare markets, announced today the first sale of ALLOCYTE ® Plus Advanced Viable Bone Matrix (“ALLOCYTE Plus” or “ALLOCYTE+”).

Sanara MedTech Announces First Sale of ALLOCYTE® Plus Advanced Viable Bone Matrix and Provides Other Product Updates

CellerateRX was approved to be sold in over 1200 new locations. BIASURGE was approved by the FDA and is set to launch commercially in Q4. TEXAGEN sales growing extremely fast (86% QoQ).

Sanara MedTech: Surgical Sales Set To Accelerate While Post Acute Care Platform Develops

FORT WORTH, TX, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that Zach Fleming, the Company's Chief Executive Officer, will present at the MicroCapClub Leadership Summit in Chicago, Illinois, on Wednesday, September 20, 2023 at 1:30 p.m. CT and at the Cantor Fitzgerald Global Healthcare Conference in New York, New York on Tuesday, September 26, 2023 at 1:00 p.m. ET.

Sanara MedTech to Participate in Two Upcoming Conferences

Sanara Medtech, Inc. (NASDAQ:SMTI ) Q2 2023 Earnings Conference Call August 15, 2023 9:00 AM ET Company Participants Callon Nichols - VP, Corporate Operations Ron Nixon - Executive Chairman Zach Fleming - CEO Mike McNeil - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Ian Cassel - MicroCap Club Operator Greetings. Welcome to the Sanara MedTech Inc. Second Quarter 2023 Results and Business Update Conference Call.

Sanara Medtech, Inc. (SMTI) Q2 2023 Earnings Call Transcript

FORT WORTH, TX, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the acquisition of certain assets related to its collagen products business.

Sanara MedTech Inc. Announces the Acquisition of Certain Assets Related to its Collagen Products Business

Sanara MedTech is growing its top line at triple-digits on an annualized basis. The company is expanding into new territories and capturing additional contract wins along the way. Valuations are supportive, and I have revised my target to $49.

Sanara MedTech: Qualified Growth Company, Market Selloff Unjustified

The heavy selling pressure might have exhausted for Sanara MedTech Inc. (SMTI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down -14.23% in 4 Weeks, Here's Why Sanara MedTech Inc. (SMTI) Looks Ripe for a Turnaround

Sanara MedTech Inc. (NASDAQ:SMTI ) Q1 2023 Earnings Conference Call May 16, 2023 9:00 AM ET Company Participants Callon Nichols - Director, Investor Relations Ron Nixon - Chairman Zach Fleming - Chief Executive Officer Mike McNeil - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Ian Cassel - IFCM Operator Good morning. And welcome to the Sanara MedTech Inc. First Quarter 2023 Results and Business Update Conference Call.

Sanara MedTech Inc. (SMTI) Q1 2023 Earnings Call Transcript

FORT WORTH, TX, May 15, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial results for the quarter ended March 31, 2023.

Sanara MedTech Inc. Announces First Quarter 2023 Results

FORT WORTH, TX, April 04, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that it has received 510(k) clearance for BIASURGE™ Advanced Surgical Solution (“BIASURGE™").

Sanara MedTech Inc. Announces 510(k) Clearance for BIASURGE™ Advanced Surgical Solution

Sanara MedTech Inc. (NASDAQ:SMTI ) Q4 2022 Earnings Conference Call March 21, 2023 9:00 AM ET Company Participants Callon Nichols - Director, Investor Relations Ron Nixon - Chairman Zachary Fleming - Chief Executive Officer Mike McNeil - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Ian Cassel - IFCM Chris Plahm - Tall Pines Capital Operator Greetings and welcome to the Sanara MedTech Incorporated Fourth Quarter and 2022 Full Year Results and Business Update Call. At this time, all participants are in a listen -only mode and a question -and-answer session will follow the formal presentation.

Sanara MedTech Inc. (SMTI) Q4 2022 Earnings Call Transcript

FORT WORTH, TX, March 20, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today its strategic, operational and financial results for the quarter and full year ended December 31, 2022.

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 Results

FORT WORTH, TX, March 06, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin care markets, announced today details for the release of its results for the quarter and year ended December 31, 2022.

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 Earnings Release and Conference Call Dates

FORT WORTH, TX, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin care markets, announced today certain unaudited preliminary results for the fourth quarter and full-year 2022.

Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2022

If you are looking for stocks that are well positioned to maintain their recent uptrend, Sanara MedTech Inc. (SMTI) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

What Makes Sanara MedTech Inc. (SMTI) a Good Fit for 'Trend Investing'

A micro cap health tech company following a path to large cap potential. A management team with vision, ownership, operational expertise, domain knowledge and that trust each other.

Sanara MedTech: A High Growth Micro Cap Disrupting The Wound And Skin Care Space

Tremendous growth during the quarter with 124% revenue upside from this time last year. Continues to expand its footprint and sales channels, pushing towards its market goals.

Sanara MedTech: Triple-Digit Revenue Upside In Q3, Expanding Footprint, Reaffirm Buy

FORT WORTH, TX, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that Zach Fleming, the Company's Chief Executive Officer, will present at the Piper Sandler 34th Annual Healthcare Conference in New York, New York on Wednesday, November 30, 2022 at 12:30 p.m. ET and will participate in a panel discussion at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference in Miami, Florida on Thursday, December 8, 2022 at 2:45 p.m. ET.

Sanara MedTech to Participate in Two Upcoming Healthcare Conferences

Sanara Medtech, Inc. (NASDAQ:SMTI ) Q3 2022 Earnings Conference Call November 15, 2022 9:00 AM ET Company Participants Callon Nichols - Director, IR Ronald Nixon - Executive Chairman Zachary Fleming - CEO Michael McNeil - CFO & Corporate Secretary Conference Call Participants Christopher Plahm - Tall Pines Capital Ian Cassel - MicroCapClub Operator Good day, ladies and gentlemen, and welcome to the Sanara MedTech Inc. Q3 2022 Earnings and Business Update. [Operator Instructions].

Sanara Medtech, Inc. (SMTI) Q3 2022 Earnings Call Transcript

FORT WORTH, TX, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today its strategic, operational and financial results for the quarter ended September 30, 2022.

Sanara MedTech Inc. Announces Third Quarter 2022 Results

FORT WORTH, TX, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI) and InfuSystem Holdings, Inc. (“InfuSystem”) (NYSE American: INFU) announced today the establishment of a partnership, SI Wound Care, LLC (“SI Wound Care”), focused on delivering a complete wound care solution targeted at improving patient outcomes, lowering the cost of care, and increasing patient and provider satisfaction. The partnership is expected to enable InfuSystem to offer innovative products including Cork Medical, LLC's (“Cork”) negative pressure wound therapy (“NPWT”) devices and supplies and Sanara's advanced wound care product line and associated services to new customers.

Sanara MedTech and InfuSystem Announce Wound Therapy Partnership

InfuSystem Hlds

InfuSystem and Sanara MedTech Announce Wound Therapy Partnership

FORT WORTH, TX, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today details for the release of its results for the quarter ended September 30, 2022.

Sanara MedTech Inc. Announces Third Quarter 2022 Earnings Release and Conference Call Dates

Sanara MedTech has caught a bid since the June roll and looks attractively priced at its current market cap. Q2 earnings were strong and demonstrated the company is capturing market share.

Sanara MedTech: Differentiated Offering With Niche Wound Care Exposure

FORT WORTH, TX, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that it has been selected to present at the 7th annual MicroCap Leadership Summit on Friday, September 16th, 2022. The MicroCap Leadership Summit is a two-day virtual event hosted by MicroCapClub.

News for Sanara MedTech Inc. Stock (SMTI)